Posted: September 27, 2010
Giordano joins P.W. Grosser as director of new energy technologies group
According to P.W. Grosser Consulting, Steve Giordano, PE, LEED AP as director of their new energy technologies group.
The newly formed group will promote renewable energy sources including wind and solar. This group will also focus on geothermal, LEED and sustainability services, carbon footprint, energy conservation, high efficiency technologies, fuel cells, cogeneration, biofuels, hydrogen and compressed natural gas (CNG) fueling stations.
By forming this new group, PWGC will enhance their ability to provide continued expertise in these service areas consistent with their sustainability focus, within the technical realm of environmental engineering, and synergistic with their current focus and clients. As director of this new group, Giordano will be tasked with strategic planning, integration of services with other company business, and supervision of staff.
Giordano joins PWGC with over 25 years of industry experience with particular expertise in alternative energy sources, energy systems and cogeneration. His background includes mechanical engineering design, managing professional staff, construction and energy services. He received his masters in Business Management from Polytechnic University, Farmingdale and a bachelors degree in Mechanical Engineering from Pratt Institute in Brooklyn.
Giordano is actively involved in the sustainable sector. He is a national member of the US Green Building Council, serving on the Board of Directors for the Long Island Chapter and is Chair for the Green Incentives Committee. He teaches LEED classes; serves as green consultant to municipalities, universities, hospitals, schools, etc.; has helped craft green legislation, ARRA stimulus Block Grants and Energy Strategies
MORE FROM Long Island
Hauppauge, NY The Suffolk County Industrial Development Agency (IDA) has granted preliminary approval of a financial incentive package that will assist a manufacturer in expanding its business by manufacturing more prescription (Rx) pharmaceuticals in addition to its existing over-the-counter